Trial Profile
A Randomised, Double Blind, Placebo Controlled, 4 Period, Incomplete Block, Crossover Study to Assess the Dose-response Curve of Intranasal Fluticasone Propionate (25, 50, 100 and 200 μg, Once Daily for 8 Days) in the Vienna Challenge Chamber for the Purpose of Investigating the Sensitivity
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Fluticasone propionate (Primary)
- Indications Seasonal allergic rhinitis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 25 Feb 2009 New trial record